A Phase 1 Study to Examine the Pharmacodynamics of Different AZD1722 Formulations

Completed · Phase 1

Conditions studied: Healthy

In brief

The study is designed to evaluate safety, tolerability, pharmacodynamics and pharmacokinetics of different formulations of AZD1722 in healthy male and female subjects taking Omeprazole.

Key facts

Study ID

NCT02249936

Run by

Ardelyx

People needed

18

Starts

2013-02-01

Expected to finish

2013-02-01

Last updated by the study team

2014-09-26

Who can join

Age: 19 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy man or woman
• Body mass index between 18 and 29.9 kg/m2

You may not qualify if…

• Diagnosis or treatment of any clinically symptomatic biochemical or structural abnormality of the gastrointestinal (GI) tract
• Any surgery on the small intestine or colon, excluding appendectomy or cholecystectomy or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs
• Clinical evidence of significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematologic, metabolic, endocrine, neurologic, psychiatric disease, or any condition that may interfere with the subject successfully completing the trial or that would present a safety risk

Where it is running

• ICON Development Solutions — Omaha, Nebraska, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.